Image Guided Therapy in the Treatment of Gliomas
| Status: | Terminated |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 7 - Any |
| Updated: | 8/5/2017 |
| Start Date: | August 2009 |
| End Date: | April 2014 |
Image Guided Adaptive Multi-modality Therapy in the Treatment of Gliomas
RATIONALE: New imaging techniques using magnetic resonance imaging give better tumor
definition, thus may lead to better tumor targeting and avoid damaging critical parts of
normal brain.
PURPOSE: This phase I/II trial is studying how well image-guided therapy works in treating
patients with newly diagnosed intracranial glioma.
definition, thus may lead to better tumor targeting and avoid damaging critical parts of
normal brain.
PURPOSE: This phase I/II trial is studying how well image-guided therapy works in treating
patients with newly diagnosed intracranial glioma.
PRIMARY OBJECTIVES:
I. To correlate the imaging findings with pathological grade following surgery in patients
with newly diagnosed intra-cranial gliomas.
SECONDARY OBJECTIVES:
I. To determine the feasibility of defining the optimal target volume for radiation therapy
using MR spectroscopy, diffusion, perfusion and functional imaging. II. To monitor
therapeutic responses following treatment using MR spectroscopy, diffusion imaging and
perfusion study.
III. To monitor changes in neurocognitive functioning following image guided therapy.
OUTLINE: Patients undergo magnetic resonance spectroscopic imaging, functional magnetic
resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then
undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5
days a week for 6 weeks. After completion of study treatment, patients are followed up every
3 months for the first year then every 6 months for another year.
I. To correlate the imaging findings with pathological grade following surgery in patients
with newly diagnosed intra-cranial gliomas.
SECONDARY OBJECTIVES:
I. To determine the feasibility of defining the optimal target volume for radiation therapy
using MR spectroscopy, diffusion, perfusion and functional imaging. II. To monitor
therapeutic responses following treatment using MR spectroscopy, diffusion imaging and
perfusion study.
III. To monitor changes in neurocognitive functioning following image guided therapy.
OUTLINE: Patients undergo magnetic resonance spectroscopic imaging, functional magnetic
resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then
undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5
days a week for 6 weeks. After completion of study treatment, patients are followed up every
3 months for the first year then every 6 months for another year.
Inclusion Criteria:
- Histologically confirmed, newly diagnosed intracranial glioma
- A diagnostic contrast enhanced CT/MRI demonstrating the lesion prior to registration
- Karnofsky performance status >= 60
- Ability to undergo MR imaging with the use of Gadolinium dye
- Patient must sign a study specific informed consent form; if the patient's mental
status precludes his/her giving informed consent, written informed consent may be
given by the patient's legal representative
Exclusion Criteria:
- Inability to obtain histological proof of glioma
- Allergy to Gadolinium contrast
- Any condition including metallic implants or cardiac pace makers that make the
candidate ineligible for MR imaging
- Any medical condition including renal or cardiac insufficiency that make the candidate
a high risk for gadolinium contrast administration
- Karnofsky performance status of =< 50
- Prior history of radiation therapy to the brain
- Pregnancy
We found this trial at
1
site
Click here to add this to my saved trials
